Keywords: ligand/allergan, start, alrt1057, trials, allergan, ligand, started
Ligand/Allergan Start ALRT1057 Trials
Article | 12 June 1995
Allergan and Ligand have started a Phase IIb clinical trials program for ALRT1057, an orally-active 9-cis-retinoic acid-based anticancer drug. In ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
